002675 Yantai Dongcheng Biochemicals
- 14.40
- -0.05-0.35%
Yantai Dongcheng Biochemicals News
Both Retail Investors Who Control a Good Portion of Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Along With Institutions Must Be Dismayed After Last Week's 3.3% Decrease
Key Insights The considerable ownership by retail investors in Yantai Dongcheng Pharmaceutical GroupLtd indicates that they collectively have a greater say in management and business strategy A tota
Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug
Yantai Dongcheng Biochemicals' (SHE:002675) unit, Yantai Lannacheng Biotechnology, will conduct clinical trials on the 177LuLNC1010 injection after receiving approval from China's National Medical Pro
Dongcheng Pharmaceutical (002675.SZ): Clinical trial application approved for ¹ Lu-LNC1010 injection
Dongcheng Pharmaceutical (002675.SZ) issued an announcement that the company's holding subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (...
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Hebei Andike, a subsidiary of Dongcheng Pharmaceutical (002675.SZ), was recognized as a specialized, special and new small and medium-sized enterprise in Hebei Province
Dongcheng Pharmaceutical (002675.SZ) announced that the company's subsidiary, Hebei Andikezheng Electronics Technology Co., Ltd. (abbreviation...
US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection
The US FDA granted Yantai Dongcheng Biochemicals' (SHE:002675) clinical trial application for its 18F-LNC1007 injection targeting tumors, according to a Tuesday filing with the Shenzhen bourse. The in
Earnings Troubles May Signal Larger Issues for Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Shareholders
The market rallied behind Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) stock, leading do a rise in the share price after its recent weak earnings report. We think that shareholders
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug
Yantai Dongcheng Biochemicals' (SHE:002675) unit, Yantai Lannacheng Biotechnology, will conduct clinical trials on the 177LuLNC1008 injection after obtaining approval from China's National Medical Pro
Is There An Opportunity With Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) 36% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Yantai Dongcheng Pharmaceutical GroupLtd fair value estimate is CN¥20.65 Yantai Dongcheng Pharmaceutical GroupLtd's CN¥13.31 share price sign
Dongcheng Pharmaceutical (002675.SZ) subsidiary, has been approved for clinical trial of ¹ Lu-LNC1008 injection
Dongcheng Pharmaceutical (002675.SZ) issued an announcement. On April 26, 2024, the company's holding subsidiary Yantai Blue...
Dongcheng Pharmaceutical (002675.SZ): Net profit of 64.327 million yuan in the first quarter increased 28.38% year-on-year
Gelonghui, April 26 | Dongcheng Pharmaceutical (002675.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 647 million yuan, down 23.90% year on year; net profit attributable to shareholders of listed companies was 64.327 million yuan, up 28.38% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 54.849,97 million yuan, up 29.40% year on year; basic earnings per share were 0.0780 yuan.
Zhitong A Share Sale Restriction and Release List | April 19
According to the Zhitong Finance App, the ban on restricted shares of 9 listed companies was lifted on April 19, with a total market value of about 12.581 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted share type, China Merchants Shekou 001979 additional A shares, corporate placement, listing 584 million, Dongcheng Pharmaceutical 002675, original shareholder placement and listing 22.3814 million, Xinte Electric 301,120A shares issuer listing 4.37 million Chen Group 300972 shares before issuance, limited circulation of 786.84 million Riying Electronics 603286 additional A shares
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore
Yantai Dongcheng Biochemicals' (SHE:002675) unit LNC Pharma will conduct phase I clinical trials on the 68Ga-LNC1007 injection in Singapore after receiving approval from the country's drug regulator,
The clinical trial of Dongcheng Pharmaceutical (002675.SZ)'s subsidiary GA-LNC1007 injection was approved by the Health Sciences Board of Singapore
Dongcheng Pharmaceutical (002675.SZ) issued an announcement. On April 9, 2024, the company's subsidiary company LNC P...
Earnings Are Growing at Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) but Shareholders Still Don't Like Its Prospects
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Dongcheng Pharmaceutical (002675.SZ): Yantai Midu plans to increase capital and expand shares and introduce 7 investors including the Advanced Manufacturing Fund
Dongcheng Pharmaceutical (002675.SZ) issued an announcement that the company's subsidiary Midu (Yantai) Biotechnology Co., Ltd. (...
Weak Financial Prospects Seem To Be Dragging Down Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Stock
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) has had a rough three months with its share price down 13%. We decided to study the company's financials to determine if the downtrend will con
Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Dongcheng Pharmaceutical to Buy Liver Drug Rights From Affiliate for 85 Million Yuan
Yantai Dongcheng Pharmaceutical Group (SHE:002675) plans to acquire the rights for the 99mTc-GSA injection and cold medicine box from affiliate Rongcheng Medical Technology Wuxi for 85 million yuan. T
Dongcheng Pharmaceutical (002675.SZ): Subsidiary company plans to introduce liver function testing and diagnostic nuclear drug products 99mtc-GSA injection and GSA cold medicine kit
Gelonghui, Feb. 20, 丨 Dongcheng Pharmaceutical (002675.SZ) announced that the company's subsidiary, Yantai Yitai Pharmaceutical Technology Co., Ltd. (“Yitai Pharmaceutical” or “Party A”), intends to use RMB 85 million in cash to purchase 99mtc-GSA injections and GSA cold medicine boxes (hereinafter referred to as the “Target Product”) held by Rongcheng Medical Technology Wuxi Co., Ltd. (“Rongcheng Medicine” or “Party B”), bought out and obtained all rights, ownership and interests in the target product, including the target product for all diagnostic, treatment fields rights, ownership, and interests in. 99mTC-GSA Note
Analysis
Price Target
No Data
